Medical Adhesive Allergens: Retrospective Analysis of Cross-Sectional Data from the North American Contact Dermatitis Group, 2001-2018.
J Am Acad Dermatol 2021;
87:1024-1032. [PMID:
34875303 DOI:
10.1016/j.jaad.2021.11.055]
[Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Revised: 11/16/2021] [Accepted: 11/29/2021] [Indexed: 10/31/2022]
Abstract
BACKGROUND
Identification of allergens causing medical adhesive contact allergy is difficult.
OBJECTIVE
Characterize the demographics, clinical characteristics, patch test results and occupational data for North American Contact Dermatitis Group (NACDG) patients with medical adhesive contact allergy.
METHODS
Retrospective study of 43,722 NACDG patients patch-tested 2001-2018, with: 1) medical adhesive (tapes/band aids/adhesive aids/suture glue) source, 2) positive patch test, and 3) final primary diagnosis of allergic contact dermatitis.
RESULTS
313 (0.7%) patients met inclusion criteria. Compared to other patients with final primary diagnosis of allergic contact dermatitis, medical adhesive allergy patients were less likely male (odds ratio 0.58, 95% confidence interval [0.45-0.77]) and/or age >40 (0.76 [0.6-0.96]). The most common NACDG screening series allergens were colophony (80.7%), balsam of Peru (3.9%), 2-hydroxyethyl methacrylate (2.7%) and carba mix (2.7%). One-fourth (79/313, 25.2%) had positive patch test reactions to supplemental allergens/materials, and 17.3% (54/313) only had reactions to supplemental allergens/materials.
LIMITATIONS
Results of comprehensive patch testing may be prone to referral population selection bias and may not be representative of the general dermatology population.
CONCLUSION
Colophony was the most common allergen. Supplemental allergens and materials should be tested in the evaluation of suspected medical adhesive contact allergy.
Collapse